Quarterly ResultMar 30, 2026, 03:07 AM
Novo Nordisk Phase 2 Trial of Amycretin Shows Up to 14.5% Weight Loss and Significant HbA1c Reduction in Type 2 Diabetes Patients
AI Summary
Novo Nordisk announced positive headline results from a phase 2 clinical trial of amycretin in people with type 2 diabetes. The trial demonstrated statistically significant weight loss of up to 14.5% at 36 weeks and significant reductions in HbA1c, with up to 89.1% achieving HbA1c levels below 7%, indicating a potentially effective new treatment option.
Key Highlights
- Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks.
- Amycretin demonstrated statistically significant reductions in HbA1c, with up to 89.1% achieving HbA1c levels below 7%.
- The trial investigated both subcutaneous and oral administration of amycretin compared to placebo in 448 people with type 2 diabetes.
- Amycretin appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies.